Mage-3 and Influenza-Matrix Peptide-Specific Cytotoxic T Cells Are Inducible in Terminal Stage HLA-A2.1+ Melanoma Patients by Mature Monocyte-Derived Dendritic Cells
Year: 2000
Type: article
Study design: Clinical Trial
Abstract: Dendritic cell (DC) vaccination, albeit still in an early stage, is a promising strategy to induce immunity to cancer. We explored whether DC can expand Ag-specific CD8+ T cells even in far-advanced stage IV melanoma patients. We found that three to five biweekly vaccinations of mature, monocyte-derived DC (three vaccinations of 6 x 106 s.c. followed by two i.v. ones of 6 and 12 x 106, respectively) pulsed with Mage-3A2.1 tumor and influenza matrix A2. 1-positive control peptides as well as the recall Ag tetanus toxoid (in three of eight patients) generated in all eight patients Ag-specific effector CD8+ T cells that were detectable in blood directly ex vivo. This is the first time that active, melanoma peptide-specific, IFN-gamma-producing, effector CD8+ T cells have been reliably observed in patients vaccinated with melanoma Ags. Therefore, our DC vaccination strategy performs an adjuvant role and encourages further optimization of this new immunization approach.
Source: The Journal of Immunology
Authors: Beatrice Schuler-Thurner, Detlef Dieckmann, Petra Keikavoussi, Armin Bender, Christian Maczek, Helmut Jonuleit, Claudia Röder, Ina Haendle, Waltraud Leisgang, Rod Dunbar, Vincenzo Cerundolo, Peter von den Driesch, Jürgen Knop, Eva B Bröcker, Alexander Enk, Eckhart Kämpgen, Gerold Schuler
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
Funders: European Commission, Deutsche Krebshilfe
OpenAlex ID: W2165951569
